BioDuro has announced the appointment of Kent Payne, Ph.D., as President of its CMC Global Solutions business unit. Kent has executive and operational experience in the CDMO market and has successfully managed start-up to well established growth business interests in both Fortune 500 and Private Equity environments.
“BioDuro’s mission in the contract research and outsourced services marketplace is to provide seamless connectivity from early stage drug discovery through IND-enabling studies, formulation development and scale up manufacturing,” said Cyrus K. Mirsaidi, CEO, BioDuro. “Kent’s addition as President to our executive team, and his extensive experience to grow businesses both organically and through M&A, will enable BioDuro to continue to focus as a full service solution provider to our current client base and help grow that client reach with new and expanded offerings.”
Kent is a business operator and leader in areas of sales, commercial manufacturing and product development. He combines strong business leadership skills, proven successful P&L track records, and a solid scientific and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. Over the last 20 years, he has successfully led the geographic expansion of businesses into Europe, Asia, South America in addition to the United States.
After earning his Ph.D. in Analytical Chemistry from Brigham Young University, Kent went on to hold positions of progressive leadership responsibility at Novartis, Monsanto and G.D. Searle.
Kent currently serves as a board member for Goodwin Biotechnologies (a biological contract manufacturer), and as a board advisor for Vitruvias Therapeutics (a specialty generic pharmaceutical business). He held prior Board and Advisory roles at Life Science Institute Inc. (a wholly-owned subsidiary of Mitsubishi Chemical Holdings), Technophar, Inc., Qualicaps, Inc. and PDS Biotechnology (PDSB).
Prior to joining BioDuro, Kent was CEO at Socorro Pharmaceuticals, a generic pharmaceutical company. He also served as President Americas at Qualicaps Inc. and as Principal Consultant and Partner at CoreFactor, providing executive strategic, licensing and operational advisory services to clients and as Vice President/General Manager at Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health).
“I am pleased to join BioDuro,” said Kent Payne, Ph.D., President, BioDuro Global CMC Solutions. “And to work alongside the executive team and Advent International, to continue the culture of customer focus while expanding BioDuro’s technical offering.”